Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Immunotherapy Future Directions (8 minutes)

Source: Video Roundtable: Immunotherapy in Endometrial Cancer
The experts share their thoughts about the future of immunotherapy in the treatment of endometrial cancer
Ana Oaknin, MD, PhD
Program Director
Domenica Lorusso, MD, PhD
person default
Mansoor Raza Mirza, MD
Released: January 4, 2021

This program is divided into several short segments which you can step through using the Video Chapters menu.
PreviousNext

Information on this Educational Activity

Program Director

Ana Oaknin, MD, PhD

Gynaecologic Cancer Programme
Vall d'Hebron Institute of Oncology (VHIO)
Hospital Universitari Vall d'Hebron
Vall d'Hebron Barcelona Hospital Campus
Barcelona, Spain

Ana Oaknin, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis Oncology, Genmab, Immungen, PharmMar, Roche, and Tesaro.

Faculty

Domenica Lorusso, MD, PhD

Associate Professor
Gynecologic Oncology Department
Clinical Research Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.
Mansoor Raza Mirza, MD

Medical Director
Department of Oncology
Chief Oncologist
The Finsen Centre
Rigshospitalet
Copenhagen University Hospital
Copenhagen, Denmark

Mansoor Raza Mirza, MD, had disclosed that he has received consulting fees from AstraZeneca, GlaxoSmithKline, Merck, and Roche and fees for non-CME/CE services from AstraZenca, GlaxoSmithKline, and Roche.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley has no real or apparent conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy Quill, PhD, has no real or apparent conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no real or apparent conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Target Audience

This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with endometrial cancer.

Goal

The goal of this activity is to improve the knowledge of global learners to apply practice-changing clinical data and expert recommendations to optimize the care of patients with endometrial cancer.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases

Ruth O'Regan, MD Lee Schwartzberg, MD, FACP Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022
Overview + Surgery and Local Radiation Therapy for Managing BCBM
Current Evidence on Therapeutic Approaches to BCBM: HER2-Positive Disease
Current Evidence on Therapeutic Approaches to BCBM: HER2-Negative Disease

Expert video from live CCO Webinar on using immune checkpoint inhibitors and antibody–drug conjugates for early-stage through metastatic TNBC

Heather McArthur, MD, MPH
Program Director Kevin Kalinsky, MD, MS Rita Nanda, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022
Immune Checkpoint Inhibitor in Advanced TNBC (26 minutes)
Immune Checkpoint Inhibitor in Early-Stage TNBC (27 minutes)
Antibody–Drug Conjugates in TNBC (26 minutes)

Commentary by Dr. Kevin Kalinsky: Sequencing checkpoint inhibitors and sacituzumab govitecan in advanced TNBC with vs without BRCA mutation, from CCO

Kevin Kalinsky, MD, MS Released: December 23, 2020

Downloadable slideset with key data from the 2020 SABCS Virtual Symposium from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: December 18, 2020

Video Chapters

Introduction
Molecular Genetics
IO in Endometrial Cancer
Immunotherapy Toxicities
Future Directions
Supported by an educational grant from
GlaxoSmithKline

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue